- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Case-Based Roundtable Meetings Spotlight: April 2 2022
Roundtable Discussion: Risk-Based Prevention of Tumor Lysis Syndrome for Hematologic Malignancies
April 30, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Hetty Carraway, MD, MBA, discussed risk factors for tumor lysis syndrome and the use of prophylactic agents.
Rini Compares Upfront Immune-Based Regimens for Renal Cell Carcinoma
April 30, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Brian Rini, MD, discussed the choice of treatment options including dual immunotherapy and tyrosine kinase inhibitors plus immunotherapy for a patient with stage IV clear cell renal cell carcinoma.
Roeker Discusses the Important Data to Consider in Managing Newly Diagnosed CLL
April 29, 2022
Clinical Articles
During a Targeted Oncology case-based event, Lindsey Roeker, MD, discussed risk assessment and frontline therapy for a patient diagnosed with chronic lymphocytic leukemia.
Roundtable Discussion: Riess Looks at the Options in Treating High PD-L1 NSCLC
April 29, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Jonathan Wesley Riess, MD, MS, discussed the case of a 72-year-old patient with non–small cell lung cancer with high PD-L1 expression.
Yazbeck Considers the Use of New Approaches in Relapsed/Refractory DLBCL
April 29, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Victor Yazbeck, MD, MS, discussed the data from recent clinical trials of tafasitamab/lenalidomide, polatuzumab vedotin, and loncastuximab tesirine for patients with relapsed/refractory diffuse large B-cell lymphoma.
Roundtable Discussion: Petrylak Examines Challenges From Updated Treatments in Metastatic Prostate Cancer
April 28, 2022
Clinical Articles
Verstovsek Discusses JAK Inhibitor Choices for Patients With Myelofibrosis
April 28, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed the use of JAK inhibitors for patients with higher-risk myelofibrosis.
Krivak Breaks Down Data for First-Line Maintenance Therapy Options in Advanced Ovarian Cancer
April 27, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Thomas C. Krivak, MD, discussed the results of studies of PARP inhibition for patients with advanced ovarian cancer.
Roundtable Discussion: Rodriguez Discusses the Differences in RET+ Lung Cancer Treatment
April 27, 2022
Clinical Articles
During a case-based roundtable event, Estelamari Rodriguez, MD, MPH, discussed the case of a patient who had lung cancer with 3 brain metastases and a RET fusion.
Roundtable Discussion: Vogl Discusses Targeted Treatment Choices in Relapsed/Refractory Multiple Myeloma
April 26, 2022
Clinical Articles
During a case-based roundtable event, Dan Vogl, MD, MSCE, discussed possible targeted therapies for a patient with relapsed/refractory multiple myeloma who had previously received several combination therapies.
Roundtable Discussion: Exploring CDK Inhibition in HR+, HER2– Early-Stage Breast Cancer
April 25, 2022
Clinical Articles
During a case-based roundtable event, Kevin Kalinsky, MD, MS, discussed clinical typing of patients with breast cancer and the results of trials of therapies for patients with HR-positive, HER2-negative breast cancer.